BACKGROUND: @entity955 ( @entity955 ) is one of the most common causes of hospital admission, with a prevalence of up to 5% of the population, increasing with advancing age. Emergency direct current cardioversion is the therapy of choice when @entity943 leads to hemodynamic compromise, but in @entity1 who are hemodynamically stable, antiarrhythmic drugs are usually given to restore sinus rhythm. HYPOTHESIS: The study was undertaken to assess the efficacy of intravenous @entity2643 in cardioversion of recent-onset @entity955 ( @entity955 ). No standard antiarrhythmic therapy has been accepted for pharmacologic cardioversion of @entity955 . @entity2643 seems to be a promising candidate, but only few randomized trials are available and the results are inconsistent. METHODS: In all, 160 @entity1 with @entity955 lasting < 24 h were randomly assigned (2:1 fashion) to the @entity2643 group (n = 106) receiving 5 mg/kg as a 30 min intravenous (i.v.) infusion, followed by i.v. infusion of 10 mg/kg during 20 h diluted in 1000 ml of 10% @entity413 with 20 IU of rapid-action insulin, 80 mEq of @entity4337 , and 8 g of @entity2400 (GIKM), or to the control group (n = 54) receiving 1000 ml of GIKM alone. Treatment was continued up to 20 h independent of sinus rhythm restoration. RESULTS: Sinus rhythm was restored 20 h after initiation of therapy in 88 (83%) @entity1 in the @entity2643 group and in 24 (44%) @entity1 in the control group (p < 0.0001). The difference between efficacy of the two treatment modalities became significant already after 8 h of therapy (53 vs. 14 @entity1 with sinus rhythm, respectively, p < 0.05). The mean dose of @entity2643 administered until sinus rhythm restoration was 740 +/- 296 mg. The presence and the type of underlying @entity299 did not influence the conversion rate in either group. In two @entity1 (1.8%) treated with @entity2643 , the return of sinus rhythm was preceded by @entity1167 . CONCLUSION: @entity2643 is effective in the termination of @entity955 lasting < 24 h. It may be particularly useful in @entity1 with @entity299 in whom class I antiarrhythmic agents may be contraindicated. During treatment, the heart rhythm should be monitored continuously.

Intravenous XXXX for cardioversion of recent-onset @entity955 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2643 :: ('MESH:D000638', 'Chemical') :: ['amiodarone', 'Amiodarone'] @entity4337 :: ('MESH:D011189', 'Chemical') :: ['potassium chloride'] @entity2400 :: ('CHEBI:32599', 'Chemical') :: ['magnesium sulphate'] @entity955 :: ('MESH:D001281', 'Disease') :: ['Atrial fibrillation', 'paroxysmal atrial fibrillation', 'AF'] @entity299 :: ('MESH:D006331', 'Disease') :: ['organic heart disease', 'heart disease'] @entity1167 :: ('MESH:D006323', 'Disease') :: ['asystole'] @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity2643 :: (MESH:D000638,Chemical) :: ['amiodarone']
